BNTC: Benitec Biopharma Inc. Stock

by  •  • Comments Off on BNTC: Benitec Biopharma Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 345.12
Enterprise Value ($M) 241.54
Book Value ($M) 97.57
Book Value / Share 3.83
Price / Book 3.54
NCAV ($M) 96.37
NCAV / Share 3.78
Price / NCAV 3.58

Profitability (mra)
Return on Invested Capital (ROIC) -0.27
Return on Assets (ROA) -1.77
Return on Equity (ROE) -2.30

Liquidity (mrq)
Quick Ratio 14.80
Current Ratio 14.80

Balance Sheet (mrq) ($M)
Current Assets 104.01
Assets 105.21
Liabilities 7.64
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
7 days ago 13G/A Nantahala Capital Management, LLC 4.39 0.00
8 days ago 13G/A Janus Henderson Group Plc 11.40 11.56
05-09 13G/A Franklin Resources Inc 16.30 -1.75
03-28 13D/A Suvretta Capital Management, Llc 49.90 9.03
02-13 13G/A HBM Healthcare Investments (Cayman) Ltd. 4.50 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT P
2025-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPOR
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-09-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2024 ☐ Transition Report under Sect

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-21 3,151 28,538 11.04
2025-05-20 5,561 33,925 16.39
2025-05-19 3,083 28,824 10.70
2025-05-16 2,085 18,386 11.34

(click for more detail)

Similar Companies
BGM – BGM Group Ltd. BIVI – BioVie Inc.
BMRA – Biomerica, Inc. BOLT – Bolt Biotherapeutics, Inc.
BON – Bon Natural Life Limited


Financial data and stock pages provided by
Fintel.io